Evidence map›Paper›PMID 28343277›Full record

ArticleDiabetologia2017

Pancreatic alpha cell-selective deletion of Tcf7l2 impairs glucagon secretion and counter-regulatory responses to hypoglycaemia in mice.

Gabriela da Silva Xavier, Angeles Mondragon, Vishnou Mourougavelou, Céline Cruciani-Guglielmacci, Jessica Denom, Pedro Luis Herrera, Christophe Magnan, Guy A Rutter

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. The α-cell in diabetes mellitus.Nature reviews. Endocrinology · 2018
    Review
  9. Review
  10. Walking a fine line between β-cell secretion and proliferation.The Journal of biological chemistry · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Gabriela da Silva XavierSection of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, London, W12 0NN, UK. g.dasilva-xavier@imperial.ac.uk.
Angeles MondragonSection of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, London, W12 0NN, UK.
Vishnou MourougavelouSection of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, London, W12 0NN, UK.
Céline Cruciani-GuglielmacciUniversité Paris Diderot Paris 7 - CNRS UMR 8251, Paris, France.
Jessica DenomUniversité Paris Diderot Paris 7 - CNRS UMR 8251, Paris, France.
Pedro Luis HerreraDepartment of Genetic Medicine & Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Christophe MagnanUniversité Paris Diderot Paris 7 - CNRS UMR 8251, Paris, France.
Guy A RutterSection of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, London, W12 0NN, UK.
Imperial College London · GBCentre National de la Recherche Scientifique · FRDélégation Paris 7 · FRUniversity of Geneva · CH

Funding

Medical Research Council MR/K001981/1Wellcome TrustWellcome Trust 081958/Z/07/ZWellcome Trust WT098424AIA
6 · The paper itself

Abstract

aims/hypothesisTranscription factor 7-like 2 (TCF7L2) is a high mobility group (HMG) box-containing transcription factor and downstream effector of the Wnt signalling pathway. SNPs in the TCF7L2 gene have previously been associated with an increased risk of type 2 diabetes in genome-wide association studies. In animal studies, loss of Tcf7l2 function is associated with defective islet beta cell function and survival. Here, we explore the role of TCF7L2 in the control of the counter-regulatory response to hypoglycaemia by generating mice with selective deletion of the Tcf7l2 gene in pancreatic alpha cells.

methodsAlpha cell-selective deletion of Tcf7l2 was achieved by crossing mice with floxed Tcf7l2 alleles to mice bearing a Cre recombinase transgene driven by the preproglucagon promoter (PPGCre), resulting in Tcf7l2AKO mice. Glucose homeostasis and hormone secretion in vivo and in vitro, and islet cell mass were measured using standard techniques.

resultsWhile glucose tolerance was unaffected in Tcf7l2AKO mice, glucose infusion rates were increased (AUC for glucose during the first 60 min period of hyperinsulinaemic-hypoglycaemic clamp test was increased by 1.98 ± 0.26-fold [p < 0.05; n = 6] in Tcf7l2AKO mice vs wild-type mice) and glucagon secretion tended to be lower (plasma glucagon: 0.40 ± 0.03-fold vs wild-type littermate controls [p < 0.01; n = 6]). Tcf7l2AKO mice displayed reduced fasted plasma glucose concentration. Glucagon release at low glucose was impaired in islets isolated from Tcf7l2AKO mice (0.37 ± 0.02-fold vs islets from wild-type littermate control mice [p < 0.01; n = 6). Alpha cell mass was also reduced (72.3 ± 20.3% [p < 0.05; n = 7) in Tcf7l2AKO mice compared with wild-type mice. CONCLUSIONS/

interpretationThe present findings demonstrate an alpha cell-autonomous role for Tcf7l2 in the control of pancreatic glucagon secretion and the maintenance of alpha cell mass and function.

Indexed as

AnimalsFemaleGlucagonGlucagon-Secreting CellsGlucoseHypoglycemiaImmunohistochemistryInsulin-Secreting CellsMaleMiceMice, KnockoutProglucagonReal-Time Polymerase Chain ReactionTranscription Factor 7-Like 2 ProteinGlucagonGlucoseProglucagonTcf7l2 protein, mouseTranscription Factor 7-Like 2 ProteinAlpha cellDiabetesGeneGlucagonGWASIslet

Identifiers

PMID28343277
PMCPMC5423960
OpenAlexW2599804953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.